Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States.
Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, United States.
Neurobiol Dis. 2018 Mar;111:26-35. doi: 10.1016/j.nbd.2017.12.005. Epub 2017 Dec 12.
Missense mutations in the multi-domain kinase LRRK2 cause late onset familial Parkinson's disease. They most commonly with classic proteinopathy in the form of Lewy bodies and Lewy neurites comprised of insoluble α-synuclein, but in rare cases can also manifest tauopathy. The normal function of LRRK2 has remained elusive, as have the cellular consequences of its mutation. Data from LRRK2 null model organisms and LRRK2-inhibitor treated animals support a physiological role for LRRK2 in regulating lysosome function. Since idiopathic and LRRK2-linked PD are associated with the intraneuronal accumulation of protein aggregates, a series of critical questions emerge. First, how do pathogenic mutations that increase LRRK2 kinase activity affect lysosome biology in neurons? Second, are mutation-induced changes in lysosome function sufficient to alter the metabolism of α-synuclein? Lastly, are changes caused by pathogenic mutation sensitive to reversal with LRRK2 kinase inhibitors? Here, we report that mutation of LRRK2 induces modest but significant changes in lysosomal morphology and acidification, and decreased basal autophagic flux when compared to WT neurons. These changes were associated with an accumulation of detergent-insoluble α-synuclein and increased neuronal release of α-synuclein and were reversed by pharmacologic inhibition of LRRK2 kinase activity. These data demonstrate a critical and disease-relevant influence of native neuronal LRRK2 kinase activity on lysosome function and α-synuclein homeostasis. Furthermore, they also suggest that lysosome dysfunction, altered neuronal α-synuclein metabolism, and the insidious accumulation of aggregated protein over decades may contribute to pathogenesis in this late-onset form of familial PD.
LRRK2 多结构域激酶的错义突变导致晚发性家族性帕金森病。它们最常见的表现为经典的路易体蛋白病,其特征为不溶性α-突触核蛋白组成的路易体和路易神经突,但在极少数情况下也可表现为tau 病。LRRK2 的正常功能仍然难以捉摸,其突变的细胞后果也是如此。来自 LRRK2 缺失模型生物和 LRRK2 抑制剂处理动物的数据支持 LRRK2 在调节溶酶体功能方面具有生理作用。由于特发性和 LRRK2 相关 PD 与蛋白聚集体在神经元内的积累有关,因此出现了一系列关键问题。首先,增加 LRRK2 激酶活性的致病突变如何影响神经元中的溶酶体生物学?其次,突变诱导的溶酶体功能变化是否足以改变α-突触核蛋白的代谢?最后,致病性突变引起的变化对 LRRK2 激酶抑制剂的逆转敏感吗?在这里,我们报告 LRRK2 的突变导致溶酶体形态和酸化的适度但显著变化,与 WT 神经元相比,基础自噬通量降低。这些变化与去污剂不溶性α-突触核蛋白的积累以及神经元α-突触核蛋白释放的增加有关,并通过 LRRK2 激酶活性的药理学抑制得到逆转。这些数据表明,天然神经元 LRRK2 激酶活性对溶酶体功能和α-突触核蛋白稳态具有关键的、与疾病相关的影响。此外,它们还表明溶酶体功能障碍、改变的神经元α-突触核蛋白代谢以及数十年间聚集蛋白的潜在积累可能导致这种迟发性家族性 PD 的发病机制。